Compile Data Set for Download or QSAR
Report error Found 383 Enz. Inhib. hit(s) with all data for entry = 9230
TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450855(US10676469, Compound 113 | US11124504, Cpd. No. 11...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450854(US10676469, Compound 112 | US11124504, Cpd. No. 11...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450886(US10676469, Compound 157 | US11124504, Cpd. No. 15...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450947(US10676469, Compound 191 | US11124504, Cpd. No. 19...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450946(US10676469, Compound 190 | US11124504, Cpd. No. 19...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450831(US10676469, Compound 89 | US11124504, Cpd. No. 89)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450862(US10676469, Compound 120 | US11124504, Cpd. No. 12...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450861(US10676469, Compound 119 | US11124504, Cpd. No. 11...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450828(US10676469, Compound 86 | US11124504, Cpd. No. 86)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450952(US10676469, Compound 215 | US11124504, Cpd. No. 21...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450950(US10676469, Compound 213 | US11124504, Cpd. No. 21...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450965(US10676469, Compound 247 | US11124504, Cpd. No. 24...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM50531908(US10676469, Compound 142 | Btrx-335140 | CYM-53093...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450934(US10676469, Compound 174 | US11124504, Cpd. No. 17...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450964(US10676469, Compound 246 | US11124504, Cpd. No. 24...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450901(US10676469, Compound 195 | US11124504, Cpd. No. 19...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450959(US10676469, Compound 243 | US11124504, Cpd. No. 24...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450833(US10676469, Compound 91 | US11124504, Cpd. No. 91)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450932(US10676469, Compound 172 | US10676469, Compound 22...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450832(US10676469, Compound 90 | US11124504, Cpd. No. 90)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM50531921(US10676469, Compound 148 | CHEMBL4544914 | US11124...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450939(US10676469, Compound 183 | US11124504, Cpd. No. 18...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450843(US10676469, Compound 101 | US11124504, Cpd. No. 10...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM50531919(US10676469, Compound 146 | CHEMBL4549826 | US11124...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450938(US10676469, Compound 182 | US11124504, Cpd. No. 18...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450842(US10676469, Compound 100 | US11124504, Cpd. No. 10...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM50531916(US10676469, Compound 145 | CHEMBL4456582 | US11124...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450937(US10676469, Compound 181 | US11124504, Cpd. No. 18...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450841(US10676469, Compound 99 | US11124504, Cpd. No. 99)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM50531915(US10676469, Compound 144 | CHEMBL4440683 | US11124...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450936(US10676469, Compound 176 | US11124504, Cpd. No. 17...)
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450823(US10676469, Compound 38 | US11124504, Cpd. No. 38)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450887(US10676469, Compound 158 | US11124504, Cpd. No. 15...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450948(US10676469, Compound 211 | US11124504, Cpd. No. 21...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450822(US10676469, Compound 37 | US11124504, Cpd. No. 37)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450914(US10676469, Compound 210 | US11124504, Cpd. No. 21...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450885(US10676469, Compound 156 | US11124504, Cpd. No. 15...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450819(US10676469, Compound 34 | US10676469, Compound 228...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450818(US10676469, Compound 33 | US11124504, Cpd. No. 33)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450817(US10676469, Compound 32 | US11124504, Cpd. No. 32)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450881(US10676469, Compound 152 | US11124504, Cpd. No. 15...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450816(US10676469, Compound 31 | US11124504, Cpd. No. 31)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450880(US10676469, Compound 151 | US11124504, Cpd. No. 15...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450957(US10676469, Compound 237b | US11124504, Cpd. No. 2...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450895(US10676469, Compound 177 | US11124504, Cpd. No. 17...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450956(US10676469, Compound 237a | US11124504, Cpd. No. 2...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450830(US10676469, Compound 88 | US11124504, Cpd. No. 88)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450955(US10676469, Compound 236b | US11124504, Cpd. No. 2...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450954(US10676469, Compound 236a | US11124504, Cpd. No. 2...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Blackthorn Therapeutics

US Patent
LigandPNGBDBM450819(US10676469, Compound 34 | US10676469, Compound 228...)
Affinity DataIC50: 5.5nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2021
Entry Details
US Patent

Displayed 1 to 50 (of 383 total ) | Next | Last >>
Jump to: